ibalizumab
Sign in to saveIbalizumab, sold under the brand name Trogarzo, is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 458273983
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- CD4
- Drug.tradename
- Trogarzo
- Drug.MedlinePlus
- a618020
- Drug.DailyMedID
- Ibalizumab
- Drug.routes_of_administration
- Intravenous (IV)
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AX23
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 680188-33-4
- Drug.DrugBank
- DB12698
- Drug.ChemSpiderID
- none
- Drug.UNII
- LT369U66CE
via Wikipedia infobox
Research
112 papersvia PubMed
~3 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- Development
- References
- External links
Ibalizumab, sold under the brand name Trogarzo, is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors.
On March 6, 2018, the U.S. Food and Drug Administration (FDA) approved ibalizumab for multidrug-resistant HIV-1. It is used in combination with other antiretroviral drugs. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Excerpted from Wikipedia’s “ibalizumab” article, available under the CC BY-SA 4.0 licence.